Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data [Seeking Alpha]
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update [Yahoo! Finance]
Galectin Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting